Tissue Proteomic Alliance Announced by Expression Pathology and ORIDIS Biomed
News May 07, 2007
The relationship combines Expression Pathology's proprietary Liquid Tissue® and DIRECTOR™ technologies, which enable mass spectrometry-based discovery and measurement of protein biomarkers in archival tissue, with ORIDIS Biomed's TISSOMICS™ research platform for high-throughput analysis of healthy and diseased patient tissue and its access to formalin-fixed tissue samples associated with longitudinal clinical and pathology information.
"We are pleased to enter into a strategic alliance with ORIDIS Biomed", said Casey Eitner, CEO, Expression Pathology. "This alliance will provide a powerful new option for drug and diagnostic developers to identify and measure protein biomarkers that relate to specific disease progression, drug response, and toxicity."
"We expect this partnership with Expression Pathology to serve the rapidly growing needs in tissue micro-proteomics", added Dr Peter Hecht, CEO ORIDIS Biomed.
"This partnership provides a unique opportunity to mine tissue archives with detailed clinical outcomes and pathology data by mass spectrometry and state-of-the-art pathology techniques."
Under the terms of the agreement both parties will offer collaborative research capabilities and services to biopharmaceutical, diagnostic and academic clients. Each party will also serve as a business development agent to its partner's technologies in its domestic geographical markets.
Official limits are in place regarding the levels of a multitude of substances that are deemed to be safe and acceptable in drinking water, but to fulfill these requirements analysts need the tools to enable them to do this. We spoke to Yan Liu, and Katariina Majamaa from Thermo Fisher Scientific about their new columns designed to enable rapid separations of contaminants prior to analysis using ion chromatography-mass spectrometry (IC-MS).READ MORE